Can polyunsaturated fatty acids regulate Polycystic Ovary Syndrome via TGF-β signalling?

Polycystic Ovary Syndrome (PCOS) is a metabolic condition that affects women in their reproductive age by altering the ovarian hormone levels, leading to infertility. Increased inflammation, insulin resistance, hyperandrogenism, irregular menses, and infertility are the causes of morbidity when PCOS...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2021-07, Vol.276, p.119416-119416, Article 119416
Main Authors: D. Prabhu, Yogamaya, Valsala Gopalakrishnan, Abilash
Format: Article
Language:English
Subjects:
Adiponectin
Animals
Chemical compounds
Complications
Diabetes mellitus
Extracellular matrix
Fatty acids
Fatty Acids, Unsaturated - metabolism
Female
Fibrillin
Growth factors
Hormones
Humans
Infertility
Inflammation
Insulin
Insulin resistance
Menstrual cycle
Metabolism
Morbidity
Mutation
Ovaries
Pathogenesis
Pharmacology
Polycystic Ovary Syndrome
Polycystic Ovary Syndrome - metabolism
Polycystic Ovary Syndrome - pathology
Polyunsaturated fatty acids
Signal transduction
Signaling
Testosterone
Therapeutic
Transforming Growth Factor beta - metabolism
Transforming growth factor-b
Transforming Growth Factor-β
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polycystic Ovary Syndrome (PCOS) is a metabolic condition that affects women in their reproductive age by altering the ovarian hormone levels, leading to infertility. Increased inflammation, insulin resistance, hyperandrogenism, irregular menses, and infertility are the causes of morbidity when PCOS is the disease in question. PCOS is considered a multifactorial disease resulting from the disruption of multiple signalling pathways. Hence, the mono-targeted drugs are hardly adequate and conventional therapeutic strategies provide only palliative care. Studies show that the consumption of polyunsaturated fatty acids (PUFAs) regulates menstrual cycle, decrease testosterone and insulin levels, and improve metabolic health. This could favourably affect diabetes and infertility. In recent years, the fibrillin-3 gene has been linked to PCOS. Fibrillins along with the molecules in the extracellular matrix modulate the Transforming Growth Factor-β (TGF-β) signalling. So, mutations in the fibrillin-3 gene could cause TGF-β dysregulation, which might further contribute to PCOS pathogenesis. Therefore, the current study aimed to understand whether PUFAs could manage PCOS via the TGF-β pathway and function as a therapeutic agent for PCOS and its complications. To understand this, we have focused on the involvement of TGF-β in PCOS pathogenesis, discussed the effect of PUFA on hormones, insulin resistance, inflammation, obesity, adiponectin, and cardiovascular conditions. Using PUFAs to target TGF-β or its receptor molecules to modulate the TGF-β production might function as a treatment option for PCOS. PUFA therapy could be a good alternative, supportive medication for PCOS. [Display omitted]
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2021.119416